Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 14/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 9/20 | 0.52 |
| ▸ | TDO2 | P48775 | 4/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5446859 | 0.82 | METAP2 (0.55) | METAP2CYP1A2TDO2IDO1 | |
| SCHEMBL4717977 | 0.81 | TSHR (0.47) | METAP2TSHR | |
| SCHEMBL25996747 | 0.80 | IDO1 (0.49) | METAP2CYP1A2TDO2IDO1TSHR | |
| SCHEMBL459193 | 0.78 | TDO2 (0.53) | TDO2IDO1TSHR | |
| SCHEMBL2924367 | 0.78 | TSHR (0.55) | TDO2IDO1TSHRCFTR | |
| SCHEMBL2592578 | 0.78 | NR4A2 (0.48) | METAP2IDO1TSHR | |
| SCHEMBL31158048 | 0.78 | TDO2 (0.53) | TDO2IDO1TSHR | |
| SCHEMBL16929719 | 0.78 | TSHR (0.44) | METAP2CYP1A2TSHRCFTR | |
| SCHEMBL15230645 | 0.77 | METAP2 (0.56) | METAP2CYP1A2TDO2IDO1 | |
| SCHEMBL15230496 | 0.77 | METAP2 (0.73) | METAP2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3323820-B1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | EPIZYME INC (US) | 2023-05-10 | — | — | EP | disclosed |
| US-20200317643-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2020-10-08 | — | — | US | disclosed |
| US-20200317643-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2020-10-08 | — | — | US | disclosed |
| US-20190300502-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2019-10-03 | — | — | US | disclosed |
| US-20190300502-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2019-10-03 | — | — | US | disclosed |
| US-10273223-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2019-04-30 | — | — | US | disclosed |
| US-10273223-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2019-04-30 | — | — | US | disclosed |
| EP-3323820-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. (US) | 2018-05-23 | — | — | EP | disclosed |
| US-20180072702-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. (US) | 2018-03-15 | — | — | US | disclosed |
| US-20180072702-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. (US) | 2018-03-15 | — | — | US | disclosed |
| US-20140057891-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057891-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. (US) | 2014-02-27 | — | — | US | disclosed |
| EP-2681216-A2 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. (US) | 2014-01-08 | — | — | EP | disclosed |
| US-8598167-B1 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2013-12-03 | — | — | US | disclosed |
| US-20130317026-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. (US) | 2013-11-28 | — | — | US | disclosed |
| WO-2012118812-A2 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. (US) | 2012-09-07 | — | — | WO | disclosed |
| US-20070078156-A1 | Derivatives of n-(1h-indazolyl)-and n-(1h-indolyl)-urea as well as related compounds as modulators of the vanilloid-1 receptor (vr1) for treatment of pain | MERCK SHARP & DOHME LTD. (GB) | 2007-04-05 | — | — | US | disclosed |
| CN-1856304-A | Heteroaromatic ureas that modulate the function of the capsaicin-1 receptor (VR1) | MERCK SHARP & DOHME (GB) | 2006-11-01 | — | — | CN | disclosed |
| EP-1675587-A2 | DERIVATIVES OF N-(1H-INDAZOLYL)- AND N-(1H-INDOLYL)-UREA AS WELL AS RELATED COMPOUNDS AS MODULATORS OF THE VANILLOID-1 RECEPTOR (VR1) FOR THE TREATMENT OF PAIN | MERCK SHARP & DOHME LTD. (GB) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005028445-A2 | DERIVATIVES OF N-(1H-INDAZOLYL)- AND N-(1H-INDOLYL)-UREA AS WELL AS RELATED COMPOUNDS AS MODULATORS OF THE VANILLOID-1 RECEPTOR (VR1) FOR THE TREATMENT OF PAIN | MERCK SHARP & DOHME LIMITED (GB) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10273223-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | CYP3A5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2D6 | METAP2 3112/4885CYP1A2 49/4885TDO2 2704/4885 |
| US-20070078156-A1 | Derivatives of n-(1h-indazolyl)-and n-(1h-indolyl)-urea as well as related compounds as modulators of the vanilloid-1 receptor (vr1) for treatment of pain | CNR1, OPRL1, SIGMAR1 | METAP2 4532/4885CYP1A2 2159/4885TDO2 1920/4885 |
| US-20180072702-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | CYP3A5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2D6 | METAP2 3112/4885CYP1A2 49/4885TDO2 2704/4885 |
| US-20140057891-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | CYP3A5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2D6 | METAP2 3112/4885CYP1A2 49/4885TDO2 2704/4885 |
| US-20200317643-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | CYP3A5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2D6 | METAP2 3112/4885CYP1A2 49/4885TDO2 2704/4885 |
| US-20190300502-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | CYP3A5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2D6 | METAP2 3112/4885CYP1A2 49/4885TDO2 2704/4885 |
| US-20130317026-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | CYP3A5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2D6 | METAP2 3112/4885CYP1A2 49/4885TDO2 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.